Korean J Gynecol Oncol Colposc.  1996 Mar;7(1):37-43.

Cisplatin/cyclophoshpamide(CP) Combination Chemotherapy with or without Adriamycin in Advanced Epithelial Ovarian Cancer

• Kang SB
• Ryu SY
• Kim JW
• Koh CW
• Pakr NH
• Song YS
• Lee HP

Abstract

Cyclophosphamide, adriamycin, and cisplatin(CAP) combination chemotherapy improved the response rate in the treatment of advanced epithelial ovarian cancer, and it has been the gold standard. However, adriamycin is a rather toxic drug, and there is still confusion concerning the choice of adriamycin to be included in optimal regimens. The present study was designed to compare the activity and toxicity of CP with CAP combination regimens in advanced epithelial ovarian cancer. From January 1988 to December 1992, 51 patients with FIGO stage III-1V epithelial ovarian cancer were treated with immediate or delayed cytoreductive surgery and chemotherapy using CAP(500/50/50mg/m2) or CP(500-1000/50mg/m2). Clinical characteristics, response rate, and toxic side-effect were compared between those CP and CAP treated patients. There were no significant differences in patient characteristics suqh as age, stage, histologic type, between two groups. Clinical complete remission rate was 48%(13/27) on CAP and 45%(11/24) on CP, and pathologic complete remission rate was 22%(6/22) on CAP regimen, and 16%(4/24) on CP regimen. There was no significant difference between patients on CAP and CP regimen in terms of clinical and pathologic complete remission rates. Hematologic toxicity was occurred in 66% of patients on CAP, 29% on CP, and cardiac toxicity was seen in 11%(3/27) only in the CAP treated patients. In conclusion, CP combination chemotherapy has comparable response rates to CAP regimen, with lower incidence of acute serious toxicities and possible disabling delayed sequelae.

MeSH Terms

Cyclophosphamide
Doxorubicin*
Drug Therapy
Drug Therapy, Combination*
Humans
Incidence
Ovarian Neoplasms*
Cyclophosphamide
Doxorubicin